RxDoctor Payments Data

Sara Mekuria, MD

Cardiovascular Disease · Frederick, MDNPI 1861650111

Payments from drug & device makers

$3,617in general payments, 2019–2025

Across 189 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$398
  • Novo Nordisk$383
  • Novartis$294
  • Amgen$273
  • Pfizer$202
  • AstraZeneca$197
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$3,56098%
  • Education$572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,617 in reported general payments places this provider in the 60th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$397,691
Medicare patients
810
Services billed
3,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban209$297,223
EntrestoSacubitril/Valsartan69$123,341
XareltoRivaroxaban33$44,478
BrilintaTicagrelor15$17,023
NexlizetBempedoic Acid/Ezetimibe17$16,316
JardianceEmpagliflozin14$16,243
Praluent PenAlirocumab16$12,866
Droxidopa16$9,933
Metoprolol Succinate325$5,318
Rosuvastatin Calcium167$4,353
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid37$3,711
Atorvastatin Calcium295$3,686
Nebivolol Hcl30$3,385
Amiodarone Hcl36$2,883
Ezetimibe52$2,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$297,223209 claims
NovartisEntresto$294$123,34169 claims
Johnson & JohnsonXarelto$95$44,47833 claims
AstraZenecaBrilinta$197$17,02315 claims
Esperion Therapeutics, Inc.Nexlizet$104$16,31617 claims
Boehringer IngelheimJardiance$164$16,24314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →